KLK3 and prostate carcinoma: Treatment of nude mice, which were injected with androgen-sensitive LNCaP prostate cancer cells, using BA resulted in a 25–38% decrease in tumor growth, along with an 88% reduction in plasma prostate-specific antigen levels [31].